Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00115973 · ClinicalTrials.gov registry record · Phase 1

A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump

A Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 1
Development phase
71
Enrollment target
6
Study locations

NCT00115973: Completed Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.

NCT00115973 is a Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 71 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00115973, a Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 1
Development phase
71 participants
Enrollment target
6
Study locations

Study Summary

This trial is conducted in the United States of America (USA). This is an in-patient trial investigating stepwise dose increase in a period of up to 3-weeks followed by a 10-week out-patient maintenance period. A telephone contact visit is scheduled as a follow-up for the final clinic visit. A subject's participation in this trial would be expected to be up to 16 weeks.

Interventions

  • DRUG insulin aspart
  • DEVICE pump

Study Locations (6)

California

  • Novo Nordisk Investigational Site - Chula Vista

Florida

  • Novo Nordisk Investigational Site - Miami

Kansas

  • Novo Nordisk Investigational Site - Witchita

New Jersey

  • Novo Nordisk Investigational Site - Willingboro

North Dakota

  • Novo Nordisk Investigational Site - Fargo

Texas

  • Novo Nordisk Investigational Site - San Antonio

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2005-06
Est. Completion 2006-01
Phase Phase 1
Novo Nordisk A/S

431 total trials

What the finished NCT00115973 record still lists

NCT00115973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which insulin aspart is the first listed.

NCT00115973 lists 6 locations in 6 states (California, Florida, Kansas).

Frequently Asked Questions

What is clinical trial NCT00115973 about?

NCT00115973 is a clinical study titled "A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump". This trial is conducted in the United States of America (USA). This is an in-patient trial investigating stepwise dose increase in a period of up to 3-weeks followed by a 10-week out-patient maintenance period. A telephone contact visit is scheduled as a follow-up for the final clinic visit. A subje...

What is the current status of trial NCT00115973?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2005-06. Estimated completion is 2006-01.

What conditions does trial NCT00115973 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes, Delivery Systems.

What interventions are being tested in trial NCT00115973?

The interventions under investigation include: insulin aspart (DRUG), pump (DEVICE).

Who is sponsoring clinical trial NCT00115973?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00115973 being conducted?

This trial has 6 study locations across California, Florida, Kansas, New Jersey, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00115973's enrollment target sits among peer trials

71 228th of 348 higher than 121 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05452889 · 71 participants · Early Phase 1

    PET Image in PAH Patients

  • NCT05766943 · 71 participants · NA

    Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

  • NCT06229678 · 71 participants · Early Phase 1

    Ketones, SGLT2, HFrEF

  • NCT06377566 · 71 participants · Phase 2

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00115973, the US trial registry maintained by the National Library of Medicine. NCT00115973 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.